Liraglutide vs Exenatide

Exenatide was the first GLP-1 receptor agonist approved and is based on exendin-4, a peptide from Gila monster saliva. Liraglutide is built on the human GLP-1 sequence with a fatty-acid chain for once-daily dosing.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

Liraglutide

A once-daily GLP-1 receptor agonist — the first long-acting GLP-1 analogue developed by acylation, predecessor to semaglutide.

BEST STUDIED FOR

Incretin & metabolic

Read the cited profile →

🧪

Exenatide

A synthetic version of exendin-4, a 39-amino-acid peptide from Gila monster venom and the first GLP-1 receptor agonist approved as a medicine.

BEST STUDIED FOR

Incretin & metabolic

Read the cited profile →

SIDE BY SIDE

	Liraglutide	Exenatide
The key difference	Human GLP-1 analogue (97% homology)	Exendin-4 from Gila monster venom
Class	Incretin & metabolic	Incretin & metabolic
Mechanism	Liraglutide carries a C16 fatty-acid side chain that allows albumin binding and self-association, extending its half-life to about 13 hours.	Exendin-4 shares about 53% homology with GLP-1 but resists DPP-4 degradation.
Status	Approved for type 2 diabetes and (at a higher dose) weight management; trialled in adolescents and children. Prescription-only in South Africa.	Approved for type 2 diabetes (twice-daily and weekly forms); extensively used in preclinical research including neuro and β-cell studies.
Reported safety signals	Gastrointestinal effects predominate; network meta-analyses compare its efficacy and safety with semaglutide and tirzepatide; weight regain after interruption is documented.	Nausea is the characteristic early effect; reviews cover pharmacokinetics, adverse effects and interactions.
A key study	Traces how acylation strategies extended GLP-1’s half-life, first in liraglutide and then semaglutide. (Front Endocrinol (Lausanne) 2019, PMID 31031702)	Reviews exenatide’s pharmacology, pharmacokinetics, efficacy and adverse effects; derived from Gila monster saliva. (Am J Health Syst Pharm 2006, PMID 16484515)

WHEN TO RESEARCH WHICH

Exenatide is historically important and studied in neurodegeneration; liraglutide has the broader metabolic and weight-management dataset. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Liraglutide] The Discovery and Development of Liraglutide and Semaglutide — Front Endocrinol (Lausanne) 2019. PMID 31031702
[Liraglutide] A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management — N Engl J Med 2015. PMID 26132939
[Liraglutide] Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies — J Clin Med 2025. PMID 40507553
[Exenatide] Exenatide — Am J Health Syst Pharm 2006. PMID 16484515
[Exenatide] Exenatide. Amylin/Eli Lilly — Curr Opin Investig Drugs 2003. PMID 12808888
[Exenatide] Harmine and exendin-4 combination therapy safely expands human β cell mass in vivo in a mouse xenograft system — Sci Transl Med 2024. PMID 38985854

FREQUENTLY ASKED

What is the difference between Liraglutide and Exenatide?

What is the regulatory status of Liraglutide and Exenatide?

Liraglutide: Approved for type 2 diabetes and (at a higher dose) weight management; trialled in adolescents and children. Prescription-only in South Africa. Exenatide: Approved for type 2 diabetes (twice-daily and weekly forms); extensively used in preclinical research including neuro and β-cell studies.

What safety signals have been reported?

Liraglutide: Gastrointestinal effects predominate; network meta-analyses compare its efficacy and safety with semaglutide and tirzepatide; weight regain after interruption is documented. Exenatide: Nausea is the characteristic early effect; reviews cover pharmacokinetics, adverse effects and interactions.

Which studies is this comparison based on?

For Liraglutide: “The Discovery and Development of Liraglutide and Semaglutide” (PMID 31031702); “A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management” (PMID 26132939); “Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies” (PMID 40507553). For Exenatide: “Exenatide” (PMID 16484515); “Exenatide. Amylin/Eli Lilly” (PMID 12808888); “Harmine and exendin-4 combination therapy safely expands human β cell mass in vivo in a mouse xenograft system” (PMID 38985854).